



For immediate release

Seinäjoki, Finland 31.01.2025

EEVIA HEALTH BRINGS FORWARD THE PUBLICATION OF THE Q4 2024 INTERIM REPORT AND EXTENDS THE SUBSCRIPTION PERIOD IN THE ONGOING RIGHTS ISSUE

THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, SINGAPORE, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Eevia Health Plc ("Eevia" or the "Company") hereby informs that publication of the Year-End 2024 Report (Q4 2024 Interim report) will be published on 4 February 2025 instead of the original date of 14 February 2025. The primary purpose is to free insiders, including PMDRs, who wish to subscribe beyond their pro-rata share from the trading ban 30 days before the release of the Interim report. At the same time, it will also bring current information to investors who are considering subscribing to the rights issue. Consequently, to give investors more time to consider an investment in the ongoing rights issue, the Board of Directors of Eevia has today decided to extend the subscription period by one week.

Publication of Q4-2024 Interim Report

Eevia's Board of Directors has decided to bring the Q4-2024 interim report forward to Tuesday, 4 February, instead of 14 February, as previously communicated in the Company's financial calendar. This is because some insiders are considering subscribing for more than their pro-rata share of the ongoing rights issue, which they are currently barred from doing due to the trading ban in the prohibition period 30 days before the release of the financial report. Therefore, to free insiders, including PMDRs, from the trading ban 30 days before the release of the Interim report, the Board has decided to publish the report earlier. Hence, the work on the report will be accelerated and completed earlier than planned.

Extension of the subscription period in the ongoing rights issue

Due to the early publication of the Q4-2024 interim report, the Company's Board of Directors has decided to extend the subscription period in the Company's ongoing rights issue by one week. The extension will allow investors more time to consider a subscription to Eevia Health after the report is released. The subscription period is therefore now decided as follows:

Updated timetable for the Rights Issue: all dates occur within 2025

| | |
|-----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| 28 January – 13 February | Trading in subscription rights. |
| 28 January – 18 February | Subscription period for the Rights Issue in Sweden. |
| 29 January – 20 February | Subscription period for the Rights Issue in Finland. |
| 28 January until the shares subscribed in the Rights Issue are registered with the Finnish Trade Register | Trading with BTA (paid subscribed share) |
| 24 February | Estimated date for publication of the outcome from the Rights Issue |
| 3 March | Registration of the new shares with the Finnish Trade Register |

Advisers

Smartius acts as the Company's legal advisor on specific aspects of the rights issue related to Finnish law. Aqurat Fondkommission is the issuing agent in Sweden.



For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967

Information about Eevia Health Plc

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing biomaterials that may dramatically impact human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) [EEVIA](#).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on [LinkedIn@EeviaHealth](#).

Important information

This press release does not constitute an offer to acquire, subscribe to, or otherwise trade in shares, subscription rights, paid subscription shares, or other securities in Eevia Health Plc. Investors must subscribe to or acquire securities only based on the information in the Exemption Document, which will be published before the start of the subscription period for the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden and Finland. This press release must not be published or distributed, directly or indirectly, to or within Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the US, or any other jurisdiction where the distribution of this press release is against the law.

Similarly, this press release does not constitute an offer to sell new shares, paid subscription shares, subscription rights, or other securities to anyone in a jurisdiction where it is not allowed to make such an offer to such a person, or where such action would require an additional prospectus, registration, or measures other than those required under Swedish law. The Exemption Document, registration slip, and other documents attributable to the Rights Issue may not be distributed to or within any country where such distribution or Rights Issue requires measures as stated in the preceding sentence, or where this would contravene the law of that country. No shares, subscription rights, paid subscription shares, or other securities have been registered or will be registered pursuant to the 1933 United States Securities Act in its current version ("the Securities Act") or securities legislation in any state or other jurisdiction of the US, and may not be offered, subscribed to, utilised, pledged, sold, resold, granted, supplied, or otherwise transferred, directly or indirectly, to or within the US, except in accordance with any applicable exemption from or by a transaction that is not covered by the registration requirements of the Securities Act and in accordance with the securities legislation in the relevant state or other jurisdiction of the US.



This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an exemption document in the form prescribed by Regulation (EU) 2024/2809 Annex IX (the "Exemption Document").

This press release may contain certain forward-looking statements that reflect the Company's current views on future events and financial and operational development. Words such as "intends", "estimates", "expects", "may", "plans", "believes", "anticipates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By nature, forward-looking statements involve known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or development, and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of Spotlight Stock Market